May. 6 at 4:01 PM
$SLP Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push
The AI drug development company has launched a technical collaboration with Nvidia to improve simulation capabilities for quantitative systems pharmacology (QSP) and pharmacokinetics/pharmacodynamics (PK/PD) applications.
The partnership aims to reduce simulation runtimes by up to 75%, allowing scientists to explore a broader range of hypotheses without the need to pre-prune models.
As part of the collaboration, the companies plan to engage select pharmaceutical partners to evaluate these capabilities in real-world drug development workflows, with initial focus on high-complexity modeling use cases.
The MACD is currently above its signal line, indicating that downside pressure is easing, which may suggest improving momentum despite the recent price drop.
This could indicate a potential for a rebound if the stock can maintain this momentum in the coming sessions.
